COMPASS Sets Course For J&J/Bayer's Xarelto In Unexplored Indications

A large new market in coronary artery and peripheral arterial disease beckons after Xarelto showed a 24% reduction in the risk of major cardiac events, a benefit that may outweigh the increase in major bleeding.

Antique bronze emblem compass, mini compass necklace pendant and binocular telescopes on ancient world map. (vintage style) — COMPASS Pointns The Way To New Sales Territory • Source: Shutterstock

BARCELONA – Janssen Pharmaceuticals Inc. and Bayer AG will make an assault on the largely uncaptured market of coronary artery and peripheral arterial disease patients after the 27,000-patient COMPASS study showed that their Factor Xa inhibitor Xarelto (rivaroxaban) as an add-on to aspirin therapy reduced the risk of major adverse cardiovascular events compared to aspirin alone.

Full data for COMPASS (Cardiovascular Outcomes for People Using Anticoagulation Strategies) in coronary artery disease (CAD) and peripheral arterial disease...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

J&J’s Trispecific Antibody For Myeloma Offers Improved Safety, Potency Over Bispecifics

20 Jun 2025

• By Alaric DeArment

The drugmaker presented data from its Phase I study of JNJ-79635322 at ASCO and EHA showing a 100% response rate in BCMA- and GPRC5D-naïve patients.

ASCO: Pushing The Frontiers Of ADCs

19 Jun 2025

• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.